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Abstract 
Background 
Centratherum anthelminticum (L.) Kuntze (scientific synonyms: Vernonia anthelmintica; 
black cumin) is one of the ingredients of an Ayurvedic preparation, called “Kayakalp”, 
commonly applied to treat skin disorders in India and Southeast Asia. Despite its well known 
anti-inflammatory property on skin diseases, the anti-cancer effect of C. anthelminticum 
seeds on skin cancer is less documented. The present study aims to investigate the anti-cancer 
effect of Centratherum anthelminticum (L.) seeds chloroform fraction (CACF) on human 
melanoma cells and to elucidate the molecular mechanism involved. 
Methods 
A chloroform fraction was extracted from C. anthelminticum (CACF). Bioactive compounds 
of the CACF were analyzed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Human melanoma cell line A375 was treated with CACF in vitro. Effects of CACF 
on growth inhibition, morphology, stress and survival of the cell were examined with MTT, 
high content screening (HSC) array scan and flow cytometry analyses. Involvement of 
intrinsic or extrinsic pathways in the CACF-induced A375 cell death mechanism was 
examined using a caspase luminescence assay. The results were further verified with different 
caspase inhibitors. In addition, Western blot analysis was performed to elucidate the changes 
in apoptosis-associated molecules. Finally, the effect of CACF on the NF-κB nuclear 
translocation ability was assayed. 
Results 
The MTT assay showed that CACF dose-dependently inhibited cell growth of A375, while 
exerted less cytotoxic effect on normal primary epithelial melanocytes. We demonstrated that 
CACF induced cell growth inhibition through apoptosis, as evidenced by cell shrinkage, 
increased annexin V staining and formation of membrane blebs. CACF treatment also 
resulted in higher reactive oxygen species (ROS) production and lower Bcl-2 expression, 
leading to decrease mitochondrial membrane potential (MMP). Disruption of the MMP 
facilitated the release of mitochondrial cytochrome c, which activates caspase-9 and 
downstream caspase-3/7, resulting in DNA fragmentation and up-regulation of p53 in 
melanoma cells. Moreover, CACF prevented TNF-α-induced NF-κB nuclear translocation, 
which further committed A375 cells toward apoptosis. 
Conclusions 
Together, our findings suggest CACF as a potential therapeutic agent against human 
melanoma malignancy. 
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Background 
Melanoma is a skin cancer that arises from the malignant transformation of melanocytes. 
Epidemiological studies showed that the incidence of melanoma is increasing at a rate faster 
than that of any other cancers worldwide [1-3]. Moreover, although early stage melanoma is 
confined to epidermis and is curable, metastasized melanoma has an unfavourable prognosis, 
where the overall survival for patients with metastatic melanoma ranges from 4.7 to 11 
months, with a median survival of 8.5 months [4]. This poor prognosis is due to the lack of 
effective treatment options [5]. 
Melanoma is often characterized by resistance to cytoxic agents which contributes to the high 
morbidity and mortality rates in patients. Therefore it is important to look for new sources of 
anti-cancer agents that exert cytotoxicity activity against melanoma cells. Plant extracts have 
been used as complementary medicine for many years. Various phytoconstituents that 
possess multiple biological and synergistical effects in the plant extracts can function to treat 
different ailments or enhance the effect of drugs [6-9]. Certain natural products have been 
applied for cancer chemoprevention to inhibit or revert carcinogenesis and to suppress the 
malignancy of cancer [10]. 
Centratherum anthelminticum (L.) Kuntze seeds (scientific synonyms: Vernonia 
anthelmintica) is commonly known as black cumin and widely used as curry spice mixtures. 
Studies have shown various pharmacological properties exhibited in the seeds of C. 
Anthelminticum, such as anti-viral, anti-filarial, anti-microbial, anti-fungal and anti-diabetic 
activities [11-13]. The black cumin seed is famous for its anti-inflammatory effect. It is used 
as an ingredient of an Ayurvedic preparation called “Kayakalp” to treat skin disorders and for 
body rejuvenation in India and Southeast Asia. Recently, a report showed that methanol 
extracts from C. anthelminticum promoted melanogenesis mainly by p38 MAPK activation, 
providing scientific explanation for its traditional use in skin disorders, such as leucoderma 
[14]. 
In comparison with other biological activities, the anti-cancer effect of CACF is relatively 
less documented. We recently reported that CACF inhibited the growth of breast cancer cell 
lines [15]; however, its effect and detailed mechanism on skin cancer is yet to be 
investigated. Hence, the aim of this study is to evaluate the therapeutic effect of CACF and 
the cellular mechanism underlying the anti-cancer effect on melanoma malignancy. 
Methods 
Plant materials 
The seeds of C. anthelminticum plant were procured from the medicinal plant cultivation 
zone of Amritum Bio-Botanica Herbs Research Laboratory Pvt. Ltd, Betul Madhya Pradesh 
India. Voucher specimen (CA-9) was deposited in the Department of Pharmacology, 
University Malaya. 
Sample extraction 
The seeds of C. anthelminticum (100 g) were pounded using grinder and extracted with 
hexane (3 × 250 ml) (Merck, Darmstadt, Germany) using soxhlet extractor. Thereafter, the 
residue obtained was further fractionated with chloroform (CHCl3) (3 × 250 ml) (Merck, 
Darmstadt, Germany) and finally with methanol (MeOH) (3 × 250 ml) (Merck, Darmstadt, 
Germany). The extract and crude fractions were collected, filtered and concentrated to 
dryness under reduced pressure in a rotary evaporator (<40°C). The hexane extract (CAHE) 
yielded 20.1 g, whereas, the defatted crude chloroform fraction (CACF) and the methanol 
fraction (CAMF) yielded 7.7 g and 11.6 g, respectively. Subsequent screening of the extract 
and fractions for their cytotoxicity, using the MTT assay, showed that the chloroform fraction 
(CACF) possesses a maximum of inhibitory effects against cancer cells. Therefore, CACF 
was chosen for further analysis. 
LC-MS/MS analysis 
Liquid chromatography (LC) analysis was carried out using UFLC prominence series 
(Shimadzu Corp., Kyoto, Japan), equipped with a quaternary pump, a vacuum degasser, an 
autosampler, a column heater-cooler and PDA detector (diode array detector, DAD). 
Separation was accomplished using an XBridge C18 column (Waters, Ireland) (2.5 µm, 2.1 × 
50 mm). About 1 mg of CACF was dissolved in 1 ml MeOH filtered through a 0.45 mm filter 
and subjected to high performance liquid chromatography (HPLC). Gradient elution was 
performed using a linear gradient solvent system consisting of solvent A (water with 0.1% 
formic acid) and solvent (B) (acetonitrile with 0.1% formic acid) as follows: 10–100% B over 
7 min, followed by isocratic elution with 100% solvent (B) from 7–12.50 min, then returned 
to 10% from 13 min at a flow rate of 0.5 ml/min. The column temperature was maintained at 
40°C and the injection volume was 10 µl. Separation of compounds was monitored with 
DAD at 254 and 190 nm and with a mass spectrometry detector. 
Mass spectrometric analysis (ESI) was carried out on LCMS-8030 triple-quadrupole mass 
spectrometer (Shimadzu, Kyoto, Japan). Liquid chromatography–tandem mass spectrometry 
(LC-MS/MS) was set in the negative and positive ionization mode with spectra acquired over 
a mass range of 50–1000 m/z. The acquisition parameters were as following: interface 
voltage, 4.5 kV; interface temperature, 250°C; desolvation line temperature, 250°C; heat 
block temperature, 400°C; desolvation gas, nitrogen; desolvation gas flow rate, 3.0 l/min; 
drying gas, nitrogen; drying gas flow rate, 15 l/min; collision gas, argon; and collision gas 
pressure, 230 kPa. 
Cell culture 
Human melanoma cell line (A375) was derived from the skin of a 54 year-old female patient 
with malignant melanoma [16]. This cell line was purchased from the American Type Culture 
Collection and cultured in DMEM media containing 10% Fetal Bovine Serum, 1% 
penicillin/streptomycin and maintained in a 37°C incubator with 5% CO2. Primary adult 
human dermal melanocytes (Cat. No.:2230) were purchased from Sciencell (Sciencell, San 
Diego, CA) and maintained in Melanocyte growth medium (Sciencell). All cells were 
maintained in an incubator at 37°C, 5% CO2. 
MTT assay 
After 24 h of CACF treatment, 50 µl of MTT solution (2 mg/ml) was transferred to each well. 
Plates were incubated for 2 h at 37°C. Supernatant was discarded and DMSO was added to 
ensure total solubility of formazan crystals. Absorbance was recorded at 570 nm with Tecan 
Infinite®200 Pro microplate reader (Tecan, Männedorf, Switzerland). 
Real time cell growth assay 
Cell proliferation was measured using xCELLigence Real Time Cellular Analysis (RTCA) 
system (Roche, Germany), as previously described [17]. Briefly, cells were seeded at density 
1 × 104 on a specialized 16-well plate with electrodes for 18 h before being treated with 100 
µl of CACF at various concentrations and continuously monitored for up to 72 h. Cell index 
values were recorded every 5–10 min by RTCA analyzer and normalized to background 
reading. 
Flow cytometry analysis 
CACF-treated cells were harvested and stained with FITC-annexin V and propidium iodide 
(PI) (BD Biosciences) in binding buffer for 15 min. Cells were immediately subjected to flow 
cytometry analyses using a FACS Canto II flow cytometer (BD Biosciences). For 
mitochondria membrane potential (MMP) measurement, CACF-treated cells were stained 
according to the BD™ MitoScreen kit protocol. Briefly, cells were stained with 0.5 ml of the 
JC-1 reagent for 15 min, washed and resuspended in 0.5 ml assay buffer prior to flow 
cytometric analysis. 
Bioluminescent assay for caspase-3/7, -8 and −9 activities 
Caspase assay was performed in triplicates using the Caspase-Glo®-3/7, -8 and −9 assay kits 
(Promega, Madison, WI) on a white 96-well microplate. A total of 1 × 104 cells were seeded 
per well and treated with 100 µl of CACF for 1, 3, 6, 12, 18, 24 and 30 h. Caspase-Glo 
reagent was then added and incubated at room temperature for 30 min. The caspase activities 
were measured using a Infinite®200 Pro microplate reader (Tecan). In the caspase inhibitor 
study, cells were treated for 1 h with inhibitors for pan-caspase (Z-VAD-FMK), caspase-3 
(Z-DEVD-FMK), caspase-9 (Z-LEHD-FMK) or caspase-8 (Z-IETD-FMK), before CACF 
treatment. 
Transmission electron miscroscopy 
Conventional electron microscopy was performed as described [18]. Cells were fixed with 
2.5% glutaraldehyde in 0.1 M sodium phosphate buffer at pH 7.4 for 1 h. The specimens are 
post-fixed in buffer containing 1% osmium tetroxide (OsO4) and 1% potassium ferrocyanide, 
dehydrated in a series of graded ethanol solutions, and embedded in epoxy resin. Ultra-thin 
sections were collected and stained with uranyl acetate and lead citrate and observed under 
transmission electron microscope (TEM, Leo Libra 120, Germany). 
Multiple cytotoxicity assay 
Cellomics Multiparameter Cytotoxicity 3 Kit was used as described previously [19]. Briefly, 
24 h post CACF treatment, MMP dye and the cell permeability dye were added to live cells 
and incubated for 30 min at 37°C. Cells were fixed, permeabilized, blocked with 1× blocking 
buffer before probing with primary cytochrome c antibody and secondary DyLightTM 649 
conjugated goat anti-mouse IgG for 1 h each. Plates were analyzed using the ArrayScan high 
content screening (HCS) system (Cellomics, PA, USA). 
ROS assay 
A total amount of 1 × 104 cells per well were seeded in 96-well plates overnight prior to 
incubation with CACF. At indicated time, 50 µl staining solution (DMEM containing 500 nM 
Hoechst 33342 and 2.5 µg/ml dihydroethidium (DHE) were added and incubated for 30 min 
at 37°C. Cells were fixed with 3.5% paraformaldeyde in PBS for 15 min, washed and 
analyzed using the HCS system (Cellomics). 
Western blot analysis 
SDS-PAGE and Western blot analyses were performed as described with slight modifications 
[20]. At 24 h post treatment, cells were lysed in RIPA buffer, loaded onto 10% 
polyacrylamide gel and transferred to microporous polyvinylidene difluoride membrane 
(Milipore). Immunoblotting was performed with the anti-Bcl-2 (1:200), anti-p53 (1:200) 
(Cell Signaling Technology, Danvers, MA), and mouse anti-β-actin (1:500) (Sigma) 
antibodies. Membranes were detected using ECL Plus Chemiluminescence Reagent 
(Amersham, Chalfont, UK). 
Statistical analysis 
Each experiment was performed at least two times. The data are presented as the mean values 
± standard deviation (SD). Statistical analysis was performed with Student’s t-test, *P < 0.05 
was considered statistically significant. 
Results 
LC-MS/MS analysis 
Compounds of CACF were successfully identified using LC-MS/MS. The UV chromatogram 
at 190 nm of CACF is shown in Figure 1. The compounds were identified by interpreting 
their mass spectra obtained via their MS, MS/MS, and UV spectra and comparing their data 
with those obtained in the literature. The identified compounds are as listed (Table 1) 
including retention times, molecular weight, protonated and deprotonated molecules 
([M+H]+ and [M-H]-), MS/MS fragments, as well as their proposed identities. Five major 
peaks were observed in the chromatograms of CACF. Three compounds were identified by 
comparing their MS and MS/MS fragments data with those in literature. Peak 2 (Figure 2A), 
detected at 2.9 min, showed [M+H]+ at m/z 361 and was tentatively assigned to the 
sesquiterpene lactone, vernodaline, previously isolated from Vernonia species [17,21,22]. Its 
MS/MS spectrum gave fragmentation ions at m/z 57 and 85 which were attributable to the 
side chain of the compound. Peak 3 (Figure 2B), retained at 3.6 min, was identified as 
vernudiflorid. It showed molecular ion at m/z 329 [M-1]- and fragmentation ions at m/z 229 
and 99 corresponding to M- C4H7CO2H. These fragmentations were consistent with those 
reported for vernudiflorid, isolated from Vernonia nudiflora [23]. Peak 5 (Rt, 4.7 min; Figure 
2C) showed [M-1]- at m/z 313 and fragment ions at m/z 213, 182, 157 and 131. It was 
tentatively identified as 12,13- dihydroxyoleic acid. Ions at m/z 182 and 131 were obtained 
from the allylic cleavage indicated the double bond at C9 and C10. Fragment ions at m/z 213 
and 157, derived from the alpha cleavage on the either side of the OH groups, h confirmed 
their positions at C12 and C13 [24,25]. This compound has been isolated previously from the 
seed of C. anthelminticum and Ochrocarpus africanus. The minor peaks 1 and 4 eluted at 2.3 
and 3.8 min, respectively, were unidentified as their fragment ions did not match with 
previously reported compounds. 
Figure 1 Chemical contents of the chloroform fraction of C. anthelminticum seeds. (A) 
Photo showing the seeds of C. anthelminticum. (B) LC chromatogram of CACF monitored at 
190 nm. Peak 2, vernodaline; peak 3, vernudiflorid; peak 5, 12,13- dihydroxyoleic acid; 
peaks 1 and 4, unknown. 
Table 1 Summary of compounds identified using MS, MS/MS, and UV spectra 
Peak # Rt (min) MW [M+H]+ or [M-H]- +/− Ions MS/MS fragments Tentative identification References 
1 2.3 378 377 - 257, 257, 230, 187 unknown  
2 3.0 360 361 + 259, 247, 86, 58 vernodaline [16,20,21] 
3 3.6 330 329 - 229, 211, 99, 83 vernudiflorid [22] 
4 3.8 346 345 - 273, 209, 197,163, 84, 57 unknown  
5 4.7 314 313 - 213, 182, 157, 131, 12,13- dihydroxyoleic acid [23,24] 
Five peaks in the chromatograms of CACF (Figure 1B) were analyzed. Retention times (Rt), molecular weight (MW), 
protonated and deprotonated molecules ([M+H]+ and [M-H]-), +/− ions, MS/MS fragments, as well as their proposed 
identities are as listed. Among the five peaks, 2, 3 and 5 were identified as vernodaline, vernudiflori and 12,13- dihydroxyol, 
whereas the identities of minor peaks 1 and 4 remained unknown. 
Figure 2 MS/MS spectra and the corresponding chemical structure of the identified 
compounds. (A) vernodaline, (B) vernuflorid, (C) 12,13- dihydroxyoleic acid. 
CACF inhibits cell proliferation of melanoma cells 
To evaluate the cytotoxic activity, CACF was tested with various doses on the human 
melanoma cell line A375 (highly metastatic, amelanotic) and normal human primary 
melanocytes. After 24 and 48 h, cell viability was analyzed using the end-point MTT assays. 
CACF exhibited greatest cytotoxicity on A375 cells with IC50 <10 µg/ml. In contrast, CACF 
was less toxic to normal primary melanocytes with IC50 >20 µg/ml, equivalent to a 2-fold 
higher selectivity compared to doxorubicin, the standard drug (Table 2). 
Table 2 IC50 of CACF or doxorubicin in melanoma A375 cells and normal primary 
melanocytes determined by MTT assays after 24 and 48 h treatment 
 CACF Doxorubicin 
IC50 (mean ± SD) µg/mL IC50 (mean ± SD) µg/mL 
 24 h 48 h 24 h 48 h 
A375 9.3 ± 2.5 8.5 ± 1.2 7.6 ± 0.8 6.2 ± 1.5 
Primary melanocytes 24.3 ± 4.6 21.5 ± 3.1 8.5 ± 2.5 7.2 ± 2.2 
Next, we monitored the pattern of real time A375 cell growth after CACF treatment for 3 
consecutive days using RTCA. In control wells, we observed an exponential increase of cell 
growth, as reflected by an increase normalized cell index (nCI) values. A375 cells treated 
with the standard drug, doxorubicin (20 µg/ml) demonstrated complete cell growth inhibition 
(Figure 3). A375 cells demonstrated a dose-dependent attenuation of cell proliferation, when 
treated with increasing concentrations of CACF (Figure 3). A375 proliferated at a slower rate 
at 6.25 µg/ml, whereas proliferation remained static when treated with 12.5 µg/ml CACF. A 
sudden decrease in nCI values was detected about 1–2 h after treatment with a high 
concentration (50 µg/ml) of CACF, indicating acute toxicity at high dosages. Altogether, both 
MTT and RTCA results suggest that CACF inhibited cell proliferation of A375 melanoma 
cells in dose- and time-dependent manner. 
Figure 3 Real time cell growth of CACF-treated melanoma cells. A375 cells were seeded 
for 18 h before addition of CACF or doxorubicin (standard drug) at indicated concentrations. 
Cell growth was monitored by RTCA for up to 90 hours. 
CACF induces apoptosis in melanoma cells 
To determine whether CACF-induced cell growth inhibition was due to apoptotic activity, we 
stained control or CACF-treated A375 cells with FITC-conjugated annexin V and PI. The 
exposure of phosphatidylinositol of the plasma membrane indicates early apoptosis and can 
be stained by annexin V. As shown in Figure 4A and B, significant increase of early (annexin 
V+, PI-) and late (annexin V+, PI+) apoptotic cells were detected in A375 following CACF 
treatment. 
Figure 4 Cell apoptosis upon CACF treatment. (A) A375 cells were treated with DMSO or 
with various concentrations of CACF for 24 h. Cells were then stained with FITC-Annexin V 
and PI to analyze early apoptotic (Annexin V+ PI-) and late apoptotic/dead (Annexin V+ 
PI+) cell fractions through flow cytometry. (B) Histogram shows the percentages of apoptotic 
cells for each treated sample at 24 h after CACF treatment. Data were mean ± SD from 2 
independent experiments (*P<0.05). (C) Transmission electron microscopy images of A375 
cells untreated or treated with 12.5 µg/ml of CACF for 12 h. (C-I) Representative image of 
untreated control cells. Intact cell membrane and abundant mitochondria were seen in the 
cytoplasm. (C-II-IV) Representative images of CACF (12.5 µg/mL)-treated cells. (C-II) 
Plasma membrane (PM) blebing and nuclear chromatin (CHR) condensation. (C-III) 
Increased numbers of clear vacuoles (V) with some lipid-filled vacuoles (LV). Reduced 
mitochondria copy number and disrupted cristae in the abnormally swollen mitochondria. (C-
IV) Increased numbers of lysosome (LY) organelles. 
We further examined cell morphology by using transmission electron microscopy. 
Micrographs demonstrated that untreated control cells presented healthy morphology, 
including intact plasma membrane, normal nucleus and abundant numbers of mitochondria 
(Figure 4C-I). Upon CACF treatment, nuclear membrane condensation, disrupted cell 
structure and severe plasma membrane blebling were observed (Figure 4C-II), suggesting 
occurence of apoptosis [26]. Other drastic morphological changes included presence of many 
vacuoles with unknown content, probably of lipid origin (Figure 4C-III). Increased lysosome 
organelles were also presented in most of the CACF-treated cells. In the same line, the 
number of mitochondria were significantly reduced (Figure 4C-IV). Note that the 
mitochondria became swollen with disorganized cristae (Figure 4C-III). These collective data 
indicated that CACF induced apoptotic cell death in melanoma A375 cells. 
CACF induces high level of ROS 
ROS is produced when a cell undergoes chemical or environmental stress, which can lead to 
modification of cytoskeletal structure and cell apoptosis. Next, we examined the ROS level in 
CACF-treated A375 cells by staining with DHE dye and viewed under HCS system. ROS 
production level was low in DMSO-treated control cells. However, CACF treatment strongly 
induced ROS production in A375 cells after 8 h (Figure 5). 
Figure 5 ROS generation in CACF-treated cells. (A) A375 cells were treated with DMSO 
or with 12.5 µg/ml concentration of CACF for 8 h, stained with DHE dye and visualized 
under HSC array scan reader. (B) Average fluorescence intensities of DHE dye in A375 cells 
treated with CACF or doxorubicin. Data were mean ± SD of fluorescence intensity readings 
measured from different photos taken (*P<0.05). 
CACF treatment reduces MMP 
Accumulating oxidative damage by ROS can affect the function and efficiency of 
mitochondria. To monitor the integrity of MMP, a membrane-permeable lipophilic cationic 
fluorescent probe, JC-1, staining was used (Figure 6A). In healthy polarized mitochondria, 
JC-1 molecules accumulate in mitochondria as aggregate, thus rendering strong red 
fluorescence emission. However, in apoptotic cells, JC-1 molecules stay as monomers in the 
cytoplasm, which can be reflected by weak red fluorescence emission [22]. Untreated A375 
cells showed high intensity of JC-1-PE (upper quadrant). After 12 h CACF treatment, we 
observed a dose-dependent reduction of JC-1-PE intensity (lower quadrant) in melanoma cell 
indicating impaired MMP (Figure 6B). 
Figure 6 JC-1 intensity in CACF-treated cells. (A) A375 cells were treated with indicated 
concentrations of CACF for 12 h. Cells were then collected, stained and analyzed with the 
flow cytometer. (B) Bar chart shows the mean fluorescence intensity of JC-1-PE. Dose-
dependent-reduction of JC-1-PE by CACF treatment was observed. Data were mean ± SD of 
fluorescence intensity readings from two independent experiments (*P<0.05). 
CACF treatment increases nuclear condensation, plasma membrane 
permeability and cytochrome c release 
Next, we utilised the multiparameter cytotoxicity kit 3 from Cellomics to examine the effect 
of CACF on other subcellular structures. For this purpose, we stained A375 cells with 
Hoechst 33342, a membrane permeability dye, MMP and cytochrome c antibody. The stained 
samples were visualized with the HSC system. In control cells, cytochrome c distributed 
evenly and colocalized with MMP. However, in CACF-treated cells, cytochrome c stained 
strongly in the cytosol, indicating CACF-induced cytochrome c release from the 
mitochondria (Figure 7A). In addition, we observed a dose-dependent increase of nuclear 
condensation, increased membrane permeability and decreased MMP stain in CACF-treated 
melanoma cells (Figure 7A-E). 
Figure 7 Effect of CACF on MMP, permeability and cytochrome c release. (A) 
Representative images of A375 cells treated with medium alone and 12.5 µg/ml of CACF, 
and stained with Hoechst for nuclear, cell permeability dye, MMP and cytochrome c. The 
images from each row were obtained from the same field of each sample (20×). (B-E) 
Average fluorescence intensities of Hoechst 33342, cell permeability dye, MMP and 
cytochrome c in A375 cells treated with CACF or standard drug doxorubicin. Data were 
mean ± SD of fluorescence intensity readings measured from different photos taken 
(*P<0.05). 
CACF induces caspase-9, -3/7 activity 
Apoptosis is a complex phenomenon that mobilizes a number of molecules and is classified 
into caspase-dependent or caspase-independent mechanisms. To examine the molecular 
mechanism underlying the apoptosis process in CACF-treated A375 cells, we incubated cells 
with aminoluciferin-labeled caspase substrate, and caspase activities were determined by 
measuring luminescence intensities. After CACF administration, the activities of caspase-3/7, 
-8 and −9 were monitored for a period of 30 h. We observed a gradual increase of caspase-9 
and 3/7 activities after 3 h treatment in A375 cells (Figure 8A). In contrast, there were no 
significant changes in caspase-8 activity throughout 30 h. 
Figure 8 Caspase activities in CACF-treated cells. (A) Caspase-3/7, -8 and −9 activities in 
the CACF (12.5 µg/mL)-treated A375 cells were measured in luminescence against various 
time intervals. Activity of caspase-9 was increased followed by caspase-3/7 activities after 
CACF treatment. (B) A375 cells were pretreated with inhibitors for pan-caspase (Z-VAD-
FMK), caspase-3 (Z-DEVD-FMK), caspase-9 (Z-LEHD-FMK) or caspase-8 (Z-IETD-FMK) 
before adding CACF. Caspase-3/7 activities in CACF-treated cells were then determined by 
luminescence assays. Data were mean ± SD of fluorescence intensity readings measured from 
different photos taken (*P<0.05). 
To further confirm this, we treated melanoma cells with specific caspase inhibitors. Pre-
treatment with the pan-caspase (Z-VAD-FMK), caspase-3 (Z-DEVD-FMK) or caspase-9 (Z-
LEHD-FMK) inhibitors, significantly impaired caspase-3/7 activity (Figure 8B). However, 
introduction of the caspase-8 inhibitor (Z-IETD-FMK) showed no significant inhibitory 
effect, suggesting that CACF-induced apoptosis occurred through the intrinsic, but not the 
extrinsic caspase pathway. 
CACF downregulates Bcl-2, upregulates p53 expression levels and inhibits 
TNF-α–induced NF-κB nuclear translocation 
The anti-apoptotic molecule Bcl-2 is a key regulator of cell death and cell proliferation. Loss 
of Bcl-2 may lead to apoptosis activity, while enforced Bcl-2 expression in apoptotic cells 
inhibits cell death. To investigate the mechanism underlying CACF-induced cell death, we 
performed Western blotting to examine the expression level of Bcl-2 in human melanoma 
cells with/without CACF treatment for 24 h. Interestingly, we found that CACF dose-
dependently downregulated Bcl-2 expression in A375 cells (Figure 9A). 
Figure 9 Bcl-2, p53 expression and TNF-α-induced NF-κB translocation in CACF-
treated cells. (A) A375 cells were treated with various concentrations of CACF for 24 h. 
Cells were harvested and lysed for Western blot analysis. Membranes were probed with anti-
Bcl-2, anti-p53 or anti-β-actin antibodies. Data were representative of two independent 
experiments. (B) A375 cells were pretreated with various concentrations of CACF prior to 
stimulation with 10 ng/ml TNF-α for 30 min. Cells were fixed, stained for NF-κB and 
visualized using HSC. (C) Bar chart showing the average fluorescence intensities of nuclear 
NF-κB in control/treated A375 cells in the absence/presence of TNF-α. 
One of the molecules that negatively regulates Bcl-2 is the p53 tumor suppressor protein. The 
p53 molecule is also frequently upregulated in response to DNA damage to exert cell cylce 
arrest [27]. Owing to this, we predicted that p53 expression could be affected upon CACF 
treatment. As shown in Figure 9A, we demonstrated that CACF markedly increased the 
expression of p53 protein in melanoma cells. 
The NF-κB pathway confers resistance to apoptosis through induction of Bcl-2 expression 
[28]. We hypothesized that reduced Bcl-2 expression may be due to inhibition of the NF-κB 
pathway. To address this, we treated A375 cells with CACF prior to addition of TNF-α. Cells 
were fixed, stained and visualized as described in the Materials and Methods. In the absence 
of TNF-α (−TNF), NF-κB remained in the cytoplasm (Figure 9B). TNF-α stimulation (+TNF) 
led to translocation of NF-κB from cytoplasm to the nucleus (Figure 9B). Interestingly, NF-
κB nuclear translocation induced by TNF-α was significantly inhibited at 12.5 µg/ml and 25 
µg/ml of CACF (Figure 9B and C). Mechanism of NF-κB nuclear translocation involves 
cascade reactions including the phosphorylation activity by IκB kinase (IKK), ubiquitin-
dependent degradation of IκB and dissociation of NF-κB from the IκB complex. Therefore, 
CACF may interrupt these activities downstream of TNF signaling pathway which prevent 
NF-κB nuclear migration. Together, these data suggest a potential interplay between NF-κB 
and apoptosis pathway molecules during CACF treatment (Figure 10). 
Figure 10 Schematic model of cell death mechanism in CACF-induced responses in 
melanoma A375 cells. CACF induces intracellular ROS production due to elevated oxidative 
stress. This initiates various intracellular changes including increased membrane permeability 
and reduced MMP which subsequently causes cytochrome c release from the mitochondria. 
Cytoplasmic cytochrome c activates caspase pathway molecules, including caspase-9 and 
caspase-3/7. Activation of caspase molecules subsequently leads to nuclear fragmentation. 
CACF treatment also triggers p53 expression that may initiate apoptosis activity through 
reduction of anti-apoptotic Bcl-2 level. On the other hand, CACF prevented NF-κB nuclear 
translocation, which could induce Bcl-2 transactivation and maintain cell survival in A375 
melanoma cells. 
Discussion 
Malignant melanoma remains a great challenge due to its significant resistance to 
chemotherapeutic treatments, which is mostly caused by an intrinsic resistance of the 
neoplastic melanocytes to undergo apoptosis [29]. Although both active and passive 
immunotherapy have been pursued vigorously over the past few decades, no melanoma 
vaccine has proven effective, and only interleukin 2 therapy has led to durable remission in 
only 5–8% of patients treated [30]. In this context, plant-derived compounds play an 
important role in the development of new anti-cancer agents against human melanoma. 
In this study, the fraction of CACF was analyzed by LCMS-IT-TOF, in order to correlate the 
activity of CACF with its components. Vernodalin, a sesquiterpene lactone, was the 
predominant compound in the CACF fraction. In 1969, an investigation by Kupchan et al. 
[21] revealed tumor inhibitory activity of vernodalin against cells derived from human 
carcinoma of the nasopharynx (KB). Similar findings were reported by Kasim et al. in 2011, 
where vernodalin indicated significant cytotoxic activity against the melanoma (Sk-mel 28) 
and ovarian cancer (CAOV-3) cell lines [31]. Recently, our group showed that vernodalin 
possessed strong cytotoxicity against the breast cancer cell line (MCF7) via the caspase 
pathway [17]. Thus, vernodalin could be the cytotoxic compound responsible for the CACF-
induced cell growth inhibition in melanoma cells, although further research is needed to 
verify this. 
Our collective data suggest that A375 melanoma cells undergo apoptotic cell death after 
treatment with CACF. During early apoptosis, the mitochondrial transmembrane depolarizes, 
followed by cytochrome c leakage which triggers caspase cascade activation [26]. Caspases 
belong to family of cysteine proteases that are divided into executioner (caspase-3 or −7) and 
initiator (caspase-8 or −9) caspases. Initiator caspase-8 is known to be activated through the 
extrinsic pathway, whereas caspase-9 is activated in the intrinsic event of mitochondrial 
cytochrome c leakage. Both of these initiator caspases lead to downstream activation of 
executioner caspase-3 or −7, which triggers cell apoptosis [32]. Incubation with CACF 
resulted in a time-dependent activation of caspase-9, whereas caspase-8 was rather unaffected 
throughout the period of study. In addition, treatments with Z-VAD-FMK, Z-DEVD-FMK or 
Z-LEHD-FMK caspase inhibitors significantly impaired caspase-3/7 activities. Thus, our 
results clearly implicate the involvement of the mitochondria-dependent intrinsic apoptotic 
pathway in CACF-induced melanoma cell death. 
ROS are highly reactive molecules that can oxidize lipids, proteins, and DNA. Mitochondria 
provide metabolic energy through oxidative phosphorylation and generate ROS as normal 
side product. Natural compounds (e.g. curcumin) or anti-cancer drug (e.g. doxorubicin) can 
upregulate intracellular ROS level and signal cells to differentiate or undergo apoptosis. 
Excessive production of ROS by CACF could destroy MMP (marked by low JC-1 staining), 
which eventually leads to release of proapoptotic transducing molecules such as cytochrome 
c. In addition, ROS could also destroy plasma membrane and DNA, resulting in higher 
membrane permeability staining and DNA fragmentation, as observed in this study [33]. 
In this study, we found that anti-cancer activity of CACF may be attributed to Bcl-2 
downregulation in melanoma cells. It is well established that Bcl-2 generally acts as a potent 
anti-apoptosis gene by controlling several key steps in apoptosis signaling, including 
formation of ion channels in biological membranes that influence permeability of 
intracellular membranes and cytochrome c release from mitochondria. Therapeutic agents 
that target Ras/Raf signaling often face a resistance problem, whereas a new strategy that 
target the survival Bcl-2 family proteins (Mcl-1 and A1) has been successful and further 
enhanced with chemotherapy [34]. Thus, Bcl-2 downregulation by CACF is an effective way 
in sensitizing human melanoma cells to apoptosis. 
In addition to the anti-apoptotic Bcl-2 molecule, we showed that p53 expression is up-
regulated in CACF-treated melanoma cells. Increased p53 may be triggered by nuclear 
fragmentation to repair DNA damage. Loss of p53 expression in mice and in human 
melanocytes has been shown to increase the proliferation and in vivo tumourigenicity, 
concordant with the role of p53 as a tumour suppressor [35,36]. Interestingly, we also showed 
that NF-κB translocation into the nucleus is inhibited by CACF, which could subsequently 
affect the expression levels of Bcl-2 and p53, because both of these molecules are downsream 
transcription targets of the NF-κB pathway [28,37,38]. 
In this study, we have demonstrated anti-cancer activity of CACF on human malignant 
melanoma A375 cell line. The limitation of the current study can be further expanded in 
future investigations by evaluating CACF therapeutic effects on other melanoma cell lines or 
in vivo xenograft model. These findings will help to explore the applicability of the plant 
extract and its constituents on skin cancers 
Conclusion 
This report shows that CACF has profound cytotoxic activity against human melanoma cells, 
but not normal melanocytes, by inducing apoptosis through modulation of anti- and pro-
apoptotic signaling pathways (Figure 10). CACF induces intracellular ROS generation, which 
causes DNA damage, increased membrane permeability and activation of a mitochondria-
dependent caspase cascade. These effects induce upregulation of p53 and downregulation of 
Bcl-2, which commit cells to apoptosis. In addition, CACF also inhibits pro-survival 
signaling by preventing NF-κB nuclear translocation. Together, our findings further support 
the development of CACF as an alternative therapeutic agent against melanoma malignancy. 
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